Clinical Report: Epidemiological Insights and Treatment Efficacy in Chronic Hepatitis C

Overview

This study assesses the demographic, clinical, and laboratory characteristics of chronic hepatitis C patients treated with direct-acting antivirals (DAAs) in Istanbul, Türkiye. It highlights the sustained virological response (SVR12) rates and the influence of genotype distribution on treatment outcomes.

Background

Chronic hepatitis C (CHC) is a significant global health issue, with approximately 50 million individuals affected worldwide. In Türkiye, the prevalence of HCV infection is around 1%, necessitating effective treatment strategies. Understanding the epidemiology and treatment efficacy of CHC is crucial for improving patient outcomes and informing public health initiatives.

Data Highlights

The study included 233 patients who completed DAA treatment and had available SVR12 data, providing insights into treatment outcomes in a real-world setting.

Key Findings

• The study cohort consisted of 233 patients with chronic hepatitis C who completed DAA therapy.
• Sustained virological response at 12 weeks (SVR12) was assessed to evaluate treatment efficacy.
• Genotype distribution varied among patients, with historical patterns influencing contemporary epidemiology.
• Adverse events related to DAA treatment were recorded, contributing to safety profiles.
• Real-world data highlighted the importance of including high-risk populations in treatment evaluations.

Clinical Implications

Clinicians should consider the evolving genotype patterns and the demographics of their patient populations when prescribing DAAs. The high SVR12 rates underscore the effectiveness of these treatments, particularly in hard-to-reach groups.

Conclusion

This study provides valuable insights into the treatment outcomes of chronic hepatitis C patients in Türkiye, emphasizing the need for ongoing monitoring of genotype trends and patient demographics to optimize care.

References

1. Open Forum Infectious Diseases, 2023 -- Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among People Who Use Drugs in Turkey
2. Infection, 2024 -- Real-World Evidence on Direct Acting Antiviral Therapy for Hepatitis C in Individuals Who Inject Drugs or Receive Opioid Substitution Treatment
3. Journal of Gastroenterology, 2023 -- Continuity of long-term follow-up in patients with chronic hepatitis C after sustained virologic response following direct-acting antiviral therapy: a nationwide real-world multicenter cohort study in Japan
4. Drugs - Real World Outcomes, 2024 -- Cancer Incidence Following Hepatitis C Virus Clearance: Findings from a Population-Based Cohort Analysis
5. Global hepatitis report 2024 Action for access in low- and middle-income countries, WHO
6. AASLD/IDSA 2023 Clinical Practice Guidance Update for Testing, Managing, and Treating Hepatitis C Virus Infection
7. | Global hepatitis report 2024 Action for access in low- and middle-income countries None
8. AASLD/IDSA 2023 Clinical Practice Guidance Update for Testing, Managing, and Treating Hepatitis C Virus Infection